Atlantic Trust Group LLC Purchases Shares of 230,946 AxoGen, Inc (AXGN)

Atlantic Trust Group LLC purchased a new stake in AxoGen, Inc (NASDAQ:AXGN) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 230,946 shares of the medical equipment provider’s stock, valued at approximately $8,430,000. Atlantic Trust Group LLC owned 0.67% of AxoGen at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of AXGN. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of AxoGen by 41.6% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,575 shares of the medical equipment provider’s stock valued at $167,000 after buying an additional 1,345 shares during the period. Princeton Capital Management LLC purchased a new stake in shares of AxoGen in the 1st quarter valued at approximately $183,000. Paloma Partners Management Co purchased a new position in shares of AxoGen during the 4th quarter worth approximately $215,000. Guggenheim Capital LLC purchased a new position in shares of AxoGen during the 4th quarter worth approximately $228,000. Finally, Gotham Asset Management LLC purchased a new position in shares of AxoGen during the 4th quarter worth approximately $249,000. 75.92% of the stock is owned by institutional investors and hedge funds.

AxoGen opened at $51.35 on Friday, MarketBeat.com reports. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.32 and a quick ratio of 2.81. The company has a market cap of $1.79 billion, a P/E ratio of -165.65 and a beta of 0.05. AxoGen, Inc has a fifty-two week low of $14.30 and a fifty-two week high of $53.95.



AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Monday, April 30th. The medical equipment provider reported ($0.11) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.11). AxoGen had a negative net margin of 18.83% and a negative return on equity of 61.66%. The firm had revenue of $17.30 million during the quarter, compared to analysts’ expectations of $17.16 million. The company’s revenue was up 41.8% compared to the same quarter last year. equities analysts forecast that AxoGen, Inc will post -0.38 EPS for the current year.

In other AxoGen news, SVP Shawn F. Mccarrey sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $43.47, for a total value of $434,700.00. Following the completion of the transaction, the senior vice president now owns 33,057 shares of the company’s stock, valued at approximately $1,436,987.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.86% of the company’s stock.

AXGN has been the subject of a number of research analyst reports. ValuEngine raised shares of AxoGen from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective (up previously from $37.00) on shares of AxoGen in a research report on Tuesday, May 1st. JMP Securities increased their price objective on shares of AxoGen from $34.00 to $43.00 and gave the stock a “market outperform” rating in a research report on Tuesday, May 1st. Lake Street Capital set a $38.00 price objective on shares of AxoGen and gave the stock a “buy” rating in a research report on Friday, March 2nd. Finally, Jefferies Financial Group increased their price objective on shares of AxoGen to $45.00 and gave the stock a “buy” rating in a research report on Monday, March 19th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $35.57.

AxoGen Profile

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc (NASDAQ:AXGN).

Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply